It is administered to patients with type 1 diabetes who lack endogenous insulin production, and to patients with type 2 diabetes, who exhibit reduced insulin secretion or response.1 As a therapeutic agent, the most common and serious side effect of insulin is hypoglycaemia.2 Hypoglycaemia can result from inappropriate insulin dosing, such as miscalculated doses or excessive infusion rates. Here, INS is linked to type 1 diabetes mellitus.